Fuller & Thaler Asset Management Inc. Sells 35,478 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Fuller & Thaler Asset Management Inc. cut its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 532,914 shares of the biotechnology company's stock after selling 35,478 shares during the quarter. Fuller & Thaler Asset Management Inc. owned about 1.19% of United Therapeutics worth $188,033,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. MML Investors Services LLC purchased a new position in United Therapeutics in the third quarter worth about $245,000. World Investment Advisors LLC bought a new stake in shares of United Therapeutics during the third quarter valued at approximately $393,000. Tidal Investments LLC increased its position in shares of United Therapeutics by 33.1% during the third quarter. Tidal Investments LLC now owns 11,272 shares of the biotechnology company's stock valued at $4,039,000 after acquiring an additional 2,803 shares in the last quarter. Tri Ri Asset Management Corp purchased a new position in United Therapeutics in the 3rd quarter worth approximately $7,686,000. Finally, Franklin Resources Inc. lifted its position in United Therapeutics by 97.7% in the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock valued at $89,532,000 after acquiring an additional 123,929 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $292.82 on Wednesday. The firm has a market capitalization of $13.15 billion, a price-to-earnings ratio of 12.86, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. The business has a fifty day moving average price of $313.33 and a 200-day moving average price of $347.74. United Therapeutics Co. has a one year low of $233.28 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the prior year, the business posted $4.36 earnings per share. On average, equities research analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $370.71, for a total value of $3,707,100.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $955,319.67. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the sale, the director now directly owns 8,480 shares in the company, valued at $2,703,424. This trade represents a 22.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 84,500 shares of company stock valued at $28,179,150 over the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on UTHR shares. JPMorgan Chase & Co. decreased their price target on United Therapeutics from $357.00 to $355.00 and set an "overweight" rating for the company in a research note on Monday. UBS Group boosted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price on the stock in a research note on Monday. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 17th. Finally, HC Wainwright restated a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. Three analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $395.67.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.